Raed Ventures

Raed Ventures is a Riyadh-based MENA early-stage specialist focusing on transformative companies, providing critical capital and operational support to scale AI-driven B2B solutions including portfolio companies such as Signit, with Seed and Series A checks in the $1M to $5M range. The fund’s positioning is operator-friendly and operationally engaged: Raed sees itself as a partner that helps Saudi and broader MENA founders navigate Vision 2030 priorities, government program alignment, and the regional commercial landscape. Healthcare relevance is digital health, health IT, AI in healthcare, and B2B platforms targeting Saudi and broader regional providers and payers. Founders pursuing biotech assets, MedTech with multi-year clearance pathways, or pure consumer wellness should look elsewhere. The right founder is a Saudi or MENA technical or commercial operator with a credible product, real revenue or strong demand-side signals, and the ambition to build at the scale Vision 2030 priorities reward. Raed is most useful when the founder values an investor with deep Saudi government program connectivity and operating relationships across the kingdom and broader Gulf. Geographic and strategic advantage is real Saudi network depth, including connectivity into PIF-aligned capital, government programs through MISA, NEOM, and the broader Vision 2030 ecosystem, and Saudi healthcare operators including major hospital networks. The fund’s positioning makes it credible with global Tier-1 co-investors that want a Saudi partner. Best entry is a warm intro from a portfolio founder, a regional co-investor such as MEVP, Sadu Capital, or +VC, or a Saudi corporate executive in the relevant ecosystem. Cold inbound is read but conversion is lower. Lead the pitch with revenue, real customer evidence, and a credible Saudi-and-Gulf expansion plan. AI healthcare founders should describe Arabic-language model performance, data residency under Saudi PDPL, regulatory posture under SFDA where relevant, and clinical or operational integration with Saudi hospitals. Caveats: Saudi Vision 2030 priorities shape the strategic landscape, and savvy founders align thoughtfully without overcommitting to government-program dependencies. Ask Raed about reserves, prorata behavior, and which Series B leads have followed it into healthcare portfolio companies. Confirm fund vintage and remaining deployment. Reference checks with current portfolio CEOs on operating support, regulator navigation, and Saudi corporate introductions are particularly worth the time. Used appropriately, Raed is one of the more credible Saudi early-stage partners for healthcare AI and B2B founders building toward Gulf and international scale.